IBBQ vs IDNA

IBBQAInvesco Nasdaq Biotechnology ETF

IDNABiShares Genomics Immunology and Healthcare ETF

In short

IBBQ The broad Nasdaq biotech benchmark, bought cheap. IBBQ tracks the whole listed biotech and pharma field, roughly 300 names, for 0.19% a year, well under half the typical fee in its category.

IDNA Most biotech ETFs hand you the US biotech index. IDNA goes narrower and wider at once: about 50 companies from developed and emerging markets, picked around genomics, immunology and bioengineering.

Stated mandate

IBBQ The Fund tracks the Nasdaq Biotechnology Index and normally invests at least 90% of its assets in index constituents. The index covers Nasdaq-listed companies classified as biotechnology or pharmaceutical companies.

IDNA The Fund seeks to track an index of developed- and emerging-market companies positioned to benefit from long-term growth and innovation in genomics, immunology, and bioengineering.

Why people hold it

• IBBQ At 0.19% a year, the lowest fee among its closest biotech rivals and less than half the category median.
• Holds roughly 300 Nasdaq-listed biotech and pharma companies, so one failed trial or one blockbuster is a slice of the fund, not the whole story.invesco.com
• Rules first: normally at least 90% of assets sit in Nasdaq Biotechnology Index constituents. No manager guessing which pipeline pays off.invesco.com
• Stands in the top quartile of the biotech and genomics funds we grade, keeping company with far larger rivals like XBI and IBB.

• IDNA The mandate is specific: an index of developed- and emerging-market companies tied to genomics, immunology and bioengineering, not a catch-all biotech basket.ishares.com
• 0.47% a year, a shade under the typical fund in its genomics-and-biotech peer group.
• About 50 holdings, so individual genomics and immunology names carry real weight instead of getting diluted inside a broad healthcare index.
• Running since 2019 under the iShares roof, and it stands in the upper half of its biotech and genomics peer group.

Worth knowing

• IBBQ Thinly traded next to the category's giants, so bid-ask spreads can widen. Limit orders matter more here than in a heavily traded fund.
• One sector, and a jumpy one: biotech and pharma prices move on trial data and regulatory decisions, a rougher ride than a broad-market fund.invesco.com
• Launched in 2021, so a shorter live record and a smaller asset base than the category's long-standing funds.

• IDNA Concentration cuts both ways: about 50 stocks in one theme, so single-company clinical news lands harder here than in a broad healthcare fund.
• Smaller and less actively traded than the category's giants, so limit orders earn their keep. Emerging-market holdings add currency and local-market risk.
• Broad biotech index funds charge less, IBBQ at 0.19% and IBB at 0.44%; the extra basis points here buy the global genomics-and-immunology tilt.

Full IBBQ profile⁠

Full IDNA profile⁠